Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMC-S118AI · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Single Ascending Dose | EXPERIMENTAL | Participants receive single ascending doses of IMC-S118AI. |
| Multiple Ascending Dose | EXPERIMENTAL | Participants receive multiple ascending doses of IMC-S118AI. |
| Name | Type | Description |
|---|---|---|
| IMC-S118AI | BIOLOGICAL | IMC-S118AI solution for infusion/injection |
Inclusion Criteria: * Body mass index (BMI): 18 to 25 kg/m2 * History of a diagnosis of T1D * HLA type: HLA-A\*02:01 * Shows signs of remaining beta-cell function Exclusion Criteria: * Non-T1D (type 2 diabetes, monogenic diabetes, and secondary diabetes) * History of recurrent hypoglycaemia due t...
IMC-S118AI is an investigational monoclonal antibody being developed for Type 1 Diabetes. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities. The drug is being studied in a controlled clinical trial to evaluate its safety and efficacy in adults with Type 1 Diabetes.
IMC-S118AI targets PD1, a receptor involved in immune regulation. By binding to PD1, the drug is designed to modulate immune responses, which may be relevant in the context of Type 1 Diabetes. The exact mechanism of action is being investigated in clinical trials.
IMC-S118AI is being developed by Immunocore Holdings plc, a biopharmaceutical company listed on the stock exchange under the ticker IMCR. The company is conducting a Phase 1 clinical trial to evaluate the drug's safety and efficacy in patients with Type 1 Diabetes.
IMC-S118AI is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 1 trial is designed to assess the drug's safety, tolerability, and preliminary efficacy in adults with Type 1 Diabetes.
IMC-S118AI is being studied in a Phase 1 clinical trial with the identifier NCT07493122. This trial, titled 'Study of IMC-S118AI in Type 1 Diabetes', is a randomized, controlled study that plans to enroll 154 participants aged 18 years and older. The trial is not yet recruiting participants.
IMC-S118AI is a distinct investigational monoclonal antibody that targets PD1. While other PD1-targeting therapies exist, IMC-S118AI is a unique asset being developed by Immunocore for Type 1 Diabetes. No alternative names for IMC-S118AI have been disclosed in the available information.